These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33994347)

  • 1. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
    Hisata S; Bando M; Homma S; Kataoka K; Ogura T; Izumi S; Sakamoto S; Watanabe K; Saito Y; Shimizu Y; Kato M; Nishioka Y; Hara H; Waseda Y; Tanino Y; Yatera K; Hashimoto S; Mukae H; Inase N;
    Respir Investig; 2021 Nov; 59(6):819-826. PubMed ID: 33994347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
    Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
    Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
    Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
    Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
    Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y
    Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
    Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
    Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
    [No Abstract]   [Full Text] [Related]  

  • 12. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
    Ogura T; Inoue Y; Azuma A; Homma S; Kondoh Y; Tanaka K; Ochiai K; Sugiyama Y; Nukiwa T
    Adv Ther; 2023 Apr; 40(4):1474-1493. PubMed ID: 36692681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
    Ntolios P; Archontogeorgis K; Anevlavis S; Bonelis K; Paxinou N; Voulgaris A; Froudarakis M; Steiropoulos P
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6326-6332. PubMed ID: 34730213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
    Sakamoto N; Hamada N; Okamoto M; Tobino K; Ichiyasu H; Ishii H; Ichikado K; Morimoto S; Hosogaya N; Mukae H
    BMJ Open; 2021 Jun; 11(6):e047249. PubMed ID: 34187824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.